Ignacio Garrido-Laguna
@GarridoLagunaMD
Followers
769
Following
651
Statuses
477
GI Oncologist, Phase 1 Director @Huntsmancancer, pancreatic cancer, RAS 🎯 @MedUNAV Alum @H12Octubre @hopkinskimmel @MDAndersonNews 🇪🇸 🇺🇸. Opinions mine
Salt Lake City, UT
Joined April 2018
Someone got lost at the U 🤣🤣priceless to find this moose after an amazing 🎿 day
3
31
302
Today clinic 2 posterchilds clinical trials make difference #pancreaticancer #1 Kras G12D ongoing complete response multi RAS inhibitor trial for 2.5 years (Cycle 40!!). #2 patient with MTAP LOF >1 year on PRMT5 inhibitor. Focus on impactful clinical research @PanCAN @letswinpc
3
5
34
@elneuropediatra @daandina Discrepo Manuel. El examen MIR debería ser eminentemente práctico, sobre clases clínicos, imágenes de ECG, radiología,… y demostrar que se está preparado para reconocer rápidamente patrones clínicos. Preguntar por una enzima? Se puede mirar en cualquier libro si fuera necesario
0
0
9
RT @VivekSubbiah: AACR elections are here🎉 Delighted to support a great friend & PARP superstar & drug developer the one & only Dr. Tim Yap…
0
6
0
RT @DanaFarber: We’re thrilled to announce the launch of Center for RAS Therapeutics to target the RAS oncogene in cancer. The first of its…
0
51
0
Got an email from a clinician referring to me as provider Garrido. I guess the next “cool”thing will be comrade Garrido. But I really prefer Dr.Garrido. Doc is still a beautiful word that captures the essence of our role.
2
0
19
RT @H12Octubre: 🥼 Rodrigo Sánchez Bayona, oncólogo de nuestra Unidad de Cáncer de Mama y Ginecológico, nombrado Chair del Comité de Jóvenes…
0
23
0
RT @DavidHongMD: Hear Ye! Hear Ye! The AACR Annual Election is here! Vote for the man, the myth for AACR Board of Directors!
0
11
0
RT @mgfakih: We have compared the performance ctDNA by Natera vs. imaging in curatively resected colorectal cancer on surveillance. Signate…
0
40
0
No, vit C infusions don’t improve survival in PDAC. Difference in OS has little to do with Vit C and likely due to imbalances between arms.. Reviewers please do your job and ask authors to highlight study limitations before publishing some like this.
4
17
40
@jordanberlin5 So true Jordan. I love this Figure with infigratinib to illustrate your point. A dosage that patients can’t tolerate beyond 50 days can’t be the right dosage.
0
0
2
RT @EileenMOReilly: Adjuvant mFOLFIRINOX for Resected Pancreatic Adenocarcinoma (PDAC): Clinical Insights and Genomic Features from a Large…
0
28
0
RT @H12Octubre: 🗓 Hoy 12 de octubre hacemos doblete: ✅ Abrimos perfil oficial! 🥁 Y te damos la bienvenida al #𝗡𝘂𝗲𝘃𝗼𝗛𝗼𝘀𝗽𝗶𝘁𝗮𝗹𝟭𝟮𝗱𝗲𝗢𝗰𝘁𝘂𝗯𝗿𝗲!…
0
118
0
@loconte @huntsmancancer @Pasca_Lab And so glad many talented investigators over the years disagreed with reviewer, thought we were just not smart enough to drug it…yet! And decided to give it a try
0
0
1
RT @ashiq_masood: Checkout new paper from our lab in @NatureGenet link: We mapped pancreatic cancer ecosystems a…
0
73
0
RT @Aiims1742: “There are not, and will never be, KRAS inhibitors” 👀 @Pasca_Lab presents a memorable reviewer comment from her 1st unfunde…
0
116
0
RT @GCarboneroLab: New hope in treating advanced grade 3 Neuroendocrine Neoplasms! 🚀 The NICE-NEC trial (GETNE-T1913) shows Nivolumab + pla…
0
16
0
RT @Julien__Dilly: Thrilled to see our study where we investigated resistance to mutant-specific KRAS inhibition in PDAC across patients sp…
0
7
0
RT @jordanberlin5: Thank you @AACR and @AACRPres for the opportunity to be at #mccr2024 to work with this amazing group. The "teachers" a…
0
2
0